Memantine Transdermal Patch Using Salt Solubilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal administration methods for memantine face challenges with variable skin penetration and loss of the active agent due to the form (free base vs. salt form) of memantine, leading to issues like dose dumping and local skin reactions, with no transdermal patches available in the United States.
Innovation Solution
A transdermal delivery system comprising an adhesive matrix with a memantine salt that is soluble in the matrix, using a counteranion such as alpha-hydroxy carboxylic acids, aliphatic carboxylic acids, or keto acids, along with a solubilizer like propylene glycol, to achieve controlled skin flux and prolonged delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If memantine is administered orally, then patient compliance is improved, but transdermal delivery control is worsened
Solution Approach 1:
The patent changes the physical-chemical parameters of memantine by converting it from free base form to salt form (memantine hydrochloride, memantine sulfate, etc.), which fundamentally alters its solubility characteristics and enables controlled transdermal delivery while maintaining patient compliance through non-invasive application
2Speed
If memantine free base is used in transdermal formulation, then skin penetration is improved, but loss of active agent is worsened
Solution Approach 1:
The patent transforms memantine from free base to salt form, changing its physical-chemical parameters to achieve optimal balance between skin penetration and stability, preventing dose dumping while maintaining therapeutic efficacy through controlled release
Solution Approach 2:
The patent creates a composite transdermal system combining memantine salt with specific adhesives and solvents (isopropyl myristate, propylene glycol) to form a stable formulation that controls both penetration and retention of the active agent
3Loss of substance
If memantine salt form is used in transdermal formulation, then loss of active agent is reduced, but skin penetration is worsened
Solution Approach 1:
The patent introduces intermediary substances (solvents like isopropyl myristate and propylene glycol, and penetration enhancers) that facilitate the delivery of memantine salt through the skin barrier, mediating between the salt form's stability and the need for effective penetration
4Ease of operation
If transdermal delivery system is developed, then patient compliance is improved, but manufacturing complexity is worsened
Solution Approach 1:
The patent merges multiple functions into a single transdermal patch formulation, combining drug delivery, adhesion, and skin protection functions in one integrated system, which simplifies manufacturing compared to multiple separate components while improving patient compliance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a controlled and sustained release of memantine over 3-7 days, achieving therapeutic blood concentrations for treating Alzheimer's disease with reduced skin flux variability and minimized loss of the active agent.
Implementation Method 1
The adhesive matrix is comprised of an adhesive polymer, a solubilizer, and an active agent such as a memantine salt. Preferably, the memantine salt is soluble in the adhesive matrix to at least about 10 mg/mL at 25° C.
Implementation Method 2
The system provides a controlled and sustained release of memantine over 3-7 days, achieving therapeutic blood concentrations for treating Alzheimer's disease with reduced skin flux variability
Data Source
AI summary
Methods, compositions, and devices for transdermally administering an active agent such as memantine are provided.